BIIB - Breakout soonBIIB is forming a tight pennant setup. Either this gonna breakout here and rally or Fakeout and crash. Let’s see..! Long anywhere here. Target #1 - 250 Target #2 - 260 Target #3 - 275 Stop loss - 225Longby just4tradin0
BIIB bear trend breakout? BIIB has broken a long running bearish trend since Jan 2023 Entry @ 223 TP1 @ 255 SL @ 200 Fundamentally strong stock hence the far off Stop loss but still a 1:2 ratio risk rewardLongby vortexTradingSolutions1
Biogen Stock Surge 4.85% on Approval For ALS DrugBiogen ( NASDAQ:BIIB ) has received a significant boost with the Food and Drug Administration's accelerated approval for Qalsody, a drug aimed at treating ALS, a debilitating muscle-wasting disease. While the approval marks a significant milestone in Biogen's efforts to address critical medical needs, the company faces challenges amidst concerns over its earnings quality and ongoing transformations under new leadership. Hope Amidst Challenges: The FDA's accelerated approval for Qalsody represents a beacon of hope for ALS patients, offering a potential treatment for a devastating disease with limited therapeutic options. Biogen's collaboration with Ionis Pharmaceuticals underscores the importance of innovative partnerships in advancing medical research and addressing unmet medical needs. However, despite this positive development, Biogen's stock performance remains under pressure amidst broader market uncertainties and investor concerns. Earnings Quality Debate: Biogen's recent earnings report, while beating expectations, has sparked debate over the quality of its earnings performance. Analysts have raised questions about the sustainability of Biogen's growth trajectory under new CEO Christopher Viehbacher, citing ongoing transformations and challenges in key therapeutic areas. The company's stock reaction to the earnings beat reflects investor caution and underscores the need for clarity regarding Biogen's long-term strategic direction. Strategic Initiatives and Pipeline Potential: Biogen's strategic initiatives, including its Alzheimer's and depression treatment efforts, holds significant potential to drive future growth. The accelerated approval of Leqembi for Alzheimer's and the optimism surrounding zuranolone for depression underscore Biogen's commitment to addressing critical neurological disorders. However, challenges persist, particularly in the multiple sclerosis franchise, where competition and generic alternatives continue to impact sales. Navigating Market Dynamics: Biogen's resilience amidst market challenges hinges on its ability to effectively execute strategic initiatives, manage portfolio dynamics, and capitalize on emerging opportunities. The company's reaffirmed outlook for full-year sales, despite headwinds in certain therapeutic areas, reflects confidence in its pipeline potential and strategic resilience. As Biogen ( NASDAQ:BIIB ) charts its course forward, investor sentiment will likely be influenced by developments in key therapeutic programs, regulatory decisions, and market dynamics.Longby DEXWireNews2
Legendary Sharkley A combination of a Shark harmonic pattern and a Gartley has emerged at the pattern completion zone. There is also bullish divergence on the RSI at the comfirmation double bottom. NASDAQ:BIIB has been oscillating between around $190-$440 since 2013 and seems to be at a good bargain price of $218 currently which is on the lower side.Longby farmerjuan111
9 year consolidation about over?Might make this one a core position over the coming months... 200 month moving average tested successfully once already.Longby chinawildman3
BIIB bull runClear simple HH and HL uptrend Entry @ 249 SL @ 229 TP 1 255 tp2 265 Longby vortexTradingSolutions1
$BIIB ShortNASDAQ:BIIB is forming a Bearish Gartley pattern after attempting a breakout. Gartly patterns are one of the most common harmonic patterns. Typically the stop-loss on these patterns can be set at the first leg of the pattern around the $270 mark.Shortby TaishisDD0
BIIB Overdue for Gap UpBIIB's at a support level, but it's also been gapping up significantly every 2-6 quarters for the past few years. Its last gap was exactly a year ago, so it's overdue for a gap up. It's also within a month of earnings, so management is likely keen on pushing for newsworthy developments. I'll be rolling far OTM calls every week until earnings given the upside for such a gap.Longby pooptart0
$BIIB: Monster trade, brace yourselvesBiogen has a monster trade brewing here, can't afford to miss this trade. I've been trading it actively since they received FDA approval for their Alzheimer's drug a while back. The current setup looks very strong and implies a massive uptrend can start from right here. Best of luck! Ivan Labrie.Longby IvanLabrieUpdated 6613
Biogen testing channel supportBiogen Inc. (BIIB) currently testing channel support, able to absorb weekly selling pressures. From here, (BIIB) can recover and turn higher to channel resistance, eliciting gains of 20-25% over the following 2 - 3 months. A settlement above this week’s high would accelerate this upward momentum. Inversely, closing below this channel support would indicate losses of 20% over the following 2 - 3 months where (BIIB) can bottom out into Q4.by SpecialeAnalysis0
BIIB earningsBiogen (BIIB) earnings are on Wednesday, July 19th, 2023, at 7:15am. Biogen (BIIB) reported Q1 March 2023 earnings of 3.40 per share on revenue of 2.5 billion. The consensus earnings estimate was 3.25 per share on revenue of 2.4 billion. The company said it continues to expect 2023 earnings of 15.00 to 16.00 per share. The current consensus earnings estimate is 15.47 per share for the year ending December 31, 2023. Q2 June 2023 Consensus: EPS = 3.70 Revenue = 2.38 B PE = 12.7 100SMA = 290 200SMA = 279 BIIB 1 day (24hr ext.) chart TTCATR 20VWMA levels: R3 = 317 R2 = 309 R1 = 302 pivot = 294 S1 = 286 S2 = 279 S3 = 271 Options data: 7/14 expiry Put Volume Total 723 Call Volume Total 2,716 Put/Call Volume Ratio 0.27 Put Open Interest Total 257 Call Open Interest Total 1,277 Put/Call Open Interest Ratio 0.20 7/21 expiry Put Volume Total 602 Call Volume Total 2,380 Put/Call Volume Ratio 0.25 Put Open Interest Total 5,614 Call Open Interest Total 10,199 Put/Call Open Interest Ratio 0.55 8/18 expiry Put Volume Total 206 Call Volume Total 726 Put/Call Volume Ratio 0.28 Put Open Interest Total 436 Call Open Interest Total 795 Put/Call Open Interest Ratio 0.55 Longby Options3601
BIIB next up target 450 and then 1080Biogen getting ready to break the long consolidation, next upside target is 450, once that is broken expect to hit 1080.Longby adisekarm2
BIIB consolidation might get to end and a new move up possible.BIIB shares might the consolidation channel and prepare a move higher. The reason would be that the market discounts the potential sales CAGR for Alzheimer's drugs, reimbursements being an issue. If the problem gets solved, BIIB gets a clear path towards higher valuation. Longby alpha625390
BIIB - Head and ShouldersOn the chart, we can see a head and shoulders forming. It's currently at the neckline, from which a breakout will activate our short position. Both MACD and RSI are showing bearish crossings. More info is shown on the chart. Good luck!Shortby vf_investment112
Alzheimer's drug, from $BIIB and EisaiAccording to MarketWatch, The FDA approved the Alzheimer's drug Legembi from Eisai and Biogen A quick look at the daily charts for $BIIB shows that it's already trading on or above major moving averages (ie. 9,21,50 SMA's). Also, seeing as this is a nice, green day for the SPY and BIIB has been beaten down recently, it's a nice long option for medium term traders and investors in general. If I were to go long, a nice R:R profit target would be the top of the Bollinger bands with a stop loss below the "fast" moving average in use. Good luck. Longby Razak_Yorou1
BIIB ShortIn downtrend, bounced back to Supply zone Current Monthly chart price range 73 - 217 Earning 7/26/2022 Estimate 4.09 Short 200 Stop 220 Target 140 Risk management is much more important than a good entry point. I am not a PRO trader. In my trading plan, the Max Risk of each short term trade should be less than 1% of an account. Shortby PlanTradePlanMMUpdated 332
BIIB daily bearish hammer end of wave 5 expect correctionOrder SELL BIIB NASDAQ.NMS Stop 278.12 LMT 278.12 will be automatically canceled at 20230401 01:00:00 EST BIIB daily bearish hammer end of wave 5 expect correction at the very leastShortby MishaSuvorovUpdated 0
$BIIB with a Neutral outlook following its earnings #Stocks The PEAD projected a Neutral outlook for $BIIB after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 75%. by EPSMomentum0
BIIB daily bearish hammerOrder SELL BIIB NASDAQ.NMS Stop 249.27 LMT 249.27 will be automatically canceled at 20230401 01:00:00 EST BIIB daily bearish hammerShortby MishaSuvorovUpdated 0
$BIIB with a Bearish outlook following its earnings #Stocks The PEAD projected a Bearish outlook for $BIIB after a Negative Under reaction following its earnings release placing the stock in drift D with an expected accuracy of 100%. Shortby EPSMomentum0
BIIB | GuidanceJournal Entry Bias: Positive. Sentiment: Optimistic. Emoji (emotion): Speculative 🧙♂️. Null Hypothesis: Buy. Alternative Hypothesis: Sell, Buy then Sell. Signals: ... Position: Day/Swing trade. Notes: I'm anticipating the market to buy the earnings surprise 07/20/22 BMO: www.estimize.com Barron's Company Overview: www.barrons.com . Other: ... Tutorial: (Q/A) What exactly is the box labeled tolerance? The box labeled tolerance is a defined range of value & time that qualifies the right to exit the trade after a profit is made; as long as the security is inside the box and above the trade's entry one could say the profit is within tolerance, likewise if the security is outside the box either because of value or time one could say the profit is not within tolerance. It's a way to add parameters to the future outcome of the journal entry (as a means to grade the journal entry) while simultaneously providing leniency in the ability to achieve success with said journal entry. About the Security: "Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA." About the Author: I'm happy to hear from my readers/audience and I encourage constructive feedback, although I'm busy I will give my best effort to reply; please don't get discouraged if I don't reply because your comment is still open for discussion with the rest of the Tradingview community. Some of my goals include building an esteemed reputation, attracting a prolific following, ranking as a Top Author, and earning the Tradingview Wizard badge. Apart from Tradingview I consider myself a financial scientist and the work I offer to the community as contributions apart of my open journal/goodwill to mankind. Disclaimer: My journal entry is not a complete prospectus, please consider it accordingly.Longby HGCRD2
Biogen BIIB options ahead of earningsLooking at the options chain today, i would buy the $255 calls with 2022-9-16 expiration date for about $3.40 premium. Looking forward to read your opinion about it. Longby TopgOptions115